Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
AssigneeU.S. Department of Veterans Affairs
InventorRobert Ferrante
Life of this patent
Estimating the term…
Abstract
A method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), includes administering a histone deacetylase (HDAC) inhibitor in a subject in need thereof. The HDAC inhibitor includes sodium butyrate or sodium phenylbutyrate.
Claims20
A method of ameliorating or abrogating the effects of a neurodegenerative disorder in a subject, comprising:
- administering a histone deacetylase (HDAC) inhibiting agent in a subject in need thereof;
- wherein the HDAC inhibiting agent comprises a butyrate.
A method of preventing neuronal death in a subject having amyotrophic lateral sclerosis, comprising:
- administering a histone deacetylase (HDAC) inhibiting agent in a subject in need thereof;
- wherein the HDAC inhibiting agent comprises a butyrate.
A method of treating a subject having amyotrophic lateral sclerosis, comprising:
- administering a histone deacetylase (HDAC) inhibiting agent in a subject in need thereof;
- wherein the HDAC inhibiting agent comprises a butyrate.
A method of protecting neural cells in a subject having a neurological disorder, comprising:
- increasing histone acetylation by administering a butyrate in a subject in need thereof.
A method of inducing expression of plκB in a subject, comprising:
- administering a histone deacetylase (HDHC) inhibiting agent in a subject in need thereof;
- and
- wherein the HDAC inhibiting agent comprises a butyrate.
A method of inducing expression of NF-κB p50 in a subject, comprising:
- a) administering a histone deacetylase (HDHC) inhibiting agent in a subject in need thereof;
- and
- b) wherein the HDAC inhibiting agent comprises a butyrate.
A method of inducing expression of bcl-2 in a subject, comprising:
- administering a histone deacetylase (HDHC) inhibiting agent in a subject in need thereof;
- and
- wherein the HDAC inhibiting agent comprises a butyrate.
Dependencies are inferred from the claim text.